Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $13.29 in the prior trading day, ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed at $13.35, up 0.45%. In other words, the price has increased by $0.45 from its previous closing price. On the day, 1.43 million shares were traded.
Ratios:
Our goal is to gain a better understanding of SPRY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 101.01. For the most recent quarter (mrq), Quick Ratio is recorded 14.04 and its Current Ratio is at 14.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $30.
On February 10, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $40.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 07 ’25 when Shawver Laura sold 50,002 shares for $12.30 per share. The transaction valued at 615,075 led to the insider holds 210,346 shares of the business.
Shawver Laura bought 50,002 shares of SPRY for $615,051 on Apr 07 ’25. On Mar 20 ’25, another insider, Karas Eric, who serves as the Chief Commercial Officer of the company, sold 10,000 shares for $14.00 each. As a result, the insider received 140,000 and left with 7,696 shares of the company.
Valuation Measures:
As of this moment, ARS’s Price-to-Earnings (P/E) ratio for their current fiscal year is 174.05. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.71 while its Price-to-Book (P/B) ratio in mrq is 5.09.
Stock Price History:
Over the past 52 weeks, SPRY has reached a high of $18.51, while it has fallen to a 52-week low of $7.55. The 50-Day Moving Average of the stock is 2.06%, while the 200-Day Moving Average is calculated to be 2.35%.
Shares Statistics:
A total of 97.95M shares are outstanding, with a floating share count of 56.10M. Insiders hold about 42.88% of the company’s shares, while institutions hold 50.88% stake in the company.
Earnings Estimates
The stock of ARS Pharmaceuticals Inc (SPRY) is currently drawing attention from 4.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.32 and low estimates of -$0.65.
Analysts are recommending an EPS of between -$1.21 and -$1.58 for the fiscal current year, implying an average EPS of -$1.43. EPS for the following year is -$0.38, with 5.0 analysts recommending between $0.24 and -$1.02.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $14.71M. There is a high estimate of $23M for the next quarter, whereas the lowest estimate is $9.5M.
A total of 6 analysts have provided revenue estimates for SPRY’s current fiscal year. The highest revenue estimate was $128.93M, while the lowest revenue estimate was $55M, resulting in an average revenue estimate of $83.16M. In the same quarter a year ago, actual revenue was $89.15MBased on 6 analysts’ estimates, the company’s revenue will be $214.44M in the next fiscal year. The high estimate is $303.6M and the low estimate is $118M.
